pipeline | autoimmune/inflammation | oncology
ALPN-101 is targeted to begin clinical studies in Q1-2019. ALPN-202 is targeted to enter the clinic in Q4-2019
Alpine Immune Sciences Announces $25 Million Private Placement
January 16, 2019 12:04 pm
Great weekend of data at #ASH18 for our ALPN-101 autoimmune/inflammatory disease program and our TIP/SIP technology… twitter.com/i/web/status/10695…
December 3, 2018 12:12 pm
© 2019 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.